Antenatal Treatment of Chylothorax and Cystic Hygroma with OK-432 in Nonimmune Hydrops fetalisChen M.a-c · Chen C.-P.d · Shih J.-C.b · Chou H.-C.e · Yu C.-L.a · Wang B.-T.c · Hsieh C.-Y.b
Departments of aMedical Genetics, bObstetrics and Gynecology, National Taiwan University Hospital, Taipei; cDepartment of Obstetrics and Gynecology and Center for Medical Genetics, Changhua Christian Hospital, Changhua; dDepartment of Obstetrics and Gynecology, Mackay Memorial Hospital, and eDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objectives: To present our experience of using OK-432 in treating fetal cystic hygroma and chylothorax complicated with nonimmune hydrops fetalis. Methods: OK-432 (Picibanil®) was injected into the fetal pleural cavity or fetal cystic hygroma. Results:Patient 1: A 23-year-old, gravida 2, para 1, was found to have a recurrent fetal chylothorax at GA 29 weeks. Serial amnioreduction and thoracocentesis was performed at GA 31, 32, 33, and 34 weeks. Intrapleural OK-432 injection was performed twice at GA 33 and 34 weeks. Cyanosis and respiratory distress were noted immediately after birth (GA 34 weeks). The baby expired despite of aggressive neonatal resuscitation. Patient 2: A 26-year-old, gravida 2, para 1, was found to have a cystic hygroma of her fetus at GA 17 weeks. Karyotype of the cystic fluid and the amniocytes were 46, XY. Fetal ascites developed at GA 22 weeks. OK-432 injection into the tumour was performed at GA 23 weeks. Stabilization of the cystic hygroma was noted throughout the pregnancy (about 3.5 cm in diameter). Serial fetal paracentesis and/or amnioreduction were performed. Karyotype of the ascites was again 46, XY. Maternal dietary modification with medium chain triglyceride was also prescribed. Chylothorax developed and the baby was born by cesareans at GA 32 weeks. Resolution of pleural effusion, ascites, and regression of cystic hygroma were noted since the 2nd day after birth. The baby had survived beyond 4 months of age at submission. Conclusion: Combination of antenatal OK-432 injection, maternal dietary modification, serial thoracocentesis plus paracentesis, together with amnioreduction and tocolysis, appeared to contribute to the success of antenatal treatment. Fetal pulmonary expansion may determine the immediate neonatal survival.
© 2005 S. Karger AG, Basel
- Ismail KM, Martin WL, Ghosh S, Whittle MJ, Kilby MD: Etiology and outcome of hydrops fetalis. J Matern Fetal Med 2001;10:175–181.
- Kennedy TL, Whitaker M, Pellitteri P, Wood WE: Cystic hygroma/lymphangioma: A rational approach to management. Laryngoscope 2001;111:1929–1937.
- Watari H, Yamada H, Fujino T, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: A case of intrauterine medical treatment for cystic hygroma. Eur J Obstet Gynecol Reprod Biol 1996;70:201–203.
- Negishi H, Yamada H, Okuyama K, Sagawa T, Makinoda S, Fujimoto S: Outcome of non-immune hydrops fetalis and a fetus with hydrothorax and/or ascites: With some trials of intrauterine treatment. J Perinat Med 1997;25:71–77.
- Samuel M, McCarthy L, Boddy SA: Efficacy and safety of OK-432 sclerotherapy for giant cystic hygroma in a newborn. Fetal Diagn Ther 2000;15:93–96.
- Ogita K, Suita S, Taguchi T, Yamanouchi T, Masumoto K, Tsukimori K, Nakano H: Outcome of fetal cystic hygroma and experience of intrauterine treatment. Fetal Diagn Ther 2001;16:105–110.
- Sasaki Y, Chiba Y: Successful intrauterine treatment of cystic hygroma colli using OK-432. Fetal Diagn Ther 2003;18:391–396.
- Kuwabara Y, Sawa R, Otsubo Y, Yoneyama Y, Asakura H, Araki T, Takeshita T: Intrauterine therapy for the acutely enlarging fetal cystic hygroma. Fetal Diagn Ther 2004;19:191–194.
- Weber AM, Philipson EH: Fetal pleural effusion: A review and meta-analysis for prognostic indicators. Obstet Gynecol 1992;79:281–286.
- Bartha JL, Comino-Delgado R: Fetal chylothorax response to maternal dietary treatment. Obstet Gynecol 2001;97:820–823.
- Chen CP, Chang TY, Wang W: Resolution of fetal bilateral chylothorax and ascites after two unilateral thoracocentesis. Ultrasound Obstet Gynecol 2001;18:401–406.
- Okawa T, Takano Y, Fujimori K, Yanagida K, Sato A: A new fetal therapy for chylothorax: Pleurodesis with OK-432. Ultrasound Obstet Gynecol 2001;18:376–377.
- Tanemura M, Nishikawa N, Kojima K, Suzuki Y, Suzumori K: A case of successful fetal therapy for congenital chylothorax by intrapleural injection of OK-432. Ultrasound Obstet Gynecol 2001;18:371–375.
- Jorgensen C, Brocks V, Bang J, Jorgensen FS, Rønsbro L: Treatment of severe fetal chylothorax associated with pronounced hydrops with intrapleural injection of OK-432. Ultrasound Obstet Gynecol 2003;21:66–69.
- Parra J, Amenedo M, Mûniz-Dîaz E, Ormo F, Simó M, Vega C, Fernández JG, Senosiain R, Moliner E, Guinovart G: A new successful therapy for fetal chylothorax by intrapleural injection of maternal blood. Ultrasound Obstet Gynecol 2003;22:290–294.
- Brito T, Oliveira C, Sousa L, Barbosa A, Pinho O, Mesquita M, Pinto R, Inocêncio A, Valente F: Congenital chylothorax: A case report. Ultrasound Obstet Gynecol 2003;21:70–71.
- Longtaker TM, Laberge JM, Dansereau J, Langer JC, Crombleholme TM, Callen PW, Golbus MS, Harrison MR: Primary fetal hydrothorax: Natural history and management. J Pediatr Surg 1989;24:573–576.
- Gembruch U, Hansmann M, Bald R, Schwanitz K, Fodisch HJ: Prenatal diagnosis and management of fetuses with cystic hygroma colli. Eur J Obstet Gynecol Reprod Biol 1988;29:241–255.
- Fujita Y, Satoh S, Nakayama H, Taguchi T, Nakano H: In utero evaluation and the long-term prognosis of living infants with cystic hygroma. Fetal Diagn Ther 2001;16:402–406.
- Tsukihara A, Tanemura M, Suzuki Y, Sato T, Tanaka T, Suzumori K: Reduction of pleural effusion by OK-432 in a fetus complicated with congenital hydrothorax. Fetal Diagn Ther 2004;19:327–331.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.